The optimal management of polycythaemia vera

British Journal of Haematology

Volumn 116, Issue 2, 2002, Pages 243-254

  Spivak, Jerry L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Diagnosis; Management; Polycythaemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CYANOCOBALAMIN; HYDROXYUREA; IBUPROFEN; PHOSPHORUS 32;

ANGIOGENESIS; BINDING AFFINITY; BLEEDING; BONE MARROW TRANSPLANTATION; CARCINOGENICITY; CELL ASSAY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; ERYTHROCYTE; ERYTHROCYTOSIS; ERYTHROMELALGIA; HEMATOCRIT; HEMATOPOIESIS; HUMAN; LEUKEMIA; LEUKOCYTE; LEUKOCYTOSIS; MYELOID METAPLASIA; PHLEBOTOMY; PLASMA VOLUME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL; SURVIVAL RATE; SYSTOLIC HYPERTENSION; THROMBOCYTE; THROMBOCYTOSIS; THROMBOSIS; TREATMENT INDICATION; VITAMIN BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKOCYTOSIS; MALE; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PREGNANCY; PREGNANCY COMPLICATIONS; PRURITUS; SPLENOMEGALY; STOMACH ULCER; THROMBOCYTOSIS;

EID: 0036178744     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03287.x     Document Type: Review

References (208)

1. Treatment of polycythaemia vera with radiophosphorus
2. Aquagenic pruritis as a presenting symptom of polycythaemia vera
3. Polycythaemia vera: Stem-cell and probable clonal origin of the disease
4. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients
5. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis
6. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis
7. Polycythaemia vera. A clinical study of 141 patients
8. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases
9. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes
10. Pregnancy in essential thrombocythaemia: Treatment and outcome of 17 pregnancies
11. The arterial complications of polycythaemia vera
12. Aspirin and risk of bleeding in patients with thrombocythemia
13. Erythropoiesis in myelofibrosis with myeloid metaplasia: Recognition of different classes of patients by erythrokinetics
14. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia
15. Outcome analysis of 34 pregnancies in women with essential thrombocythemia
16. Abnormalities of platelet function in patients with polycythaemia vera
17. Therapeutic recommendations in polycythaemia vera based on Polycythaemia Vera Study group protocols
18. Increased incidence of acute leukemia in polycythaemia vera associated with chlorambucil therapy
19. Diagnosis and classification of the polycythaemias
20. Louis Wasserman and the history of polycythaemia vera
21. 32P
22. 131 tagged human serum albumin in simultaneous blood Volume determinations
23. Androgens and human blood volume changes. Comparison in normal and various anemic states
24. Does iron deficiency in treated polycythaemia vera affect whole blood viscosity?
25. Relative polycythaemia
26. Thromboembolic risk of postsplenectomy thrombocytosis
27. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: Are safer drugs available?
28. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases
29. Busulphan treatment of polycythaemia vera
30. Thrombosis of the portal vein following splenectomy for myeloid metaplasia
31. Polycythaemia vera and water-induced pruritus: Evidence against mast cell involvement
32. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma
33. Busulfan
34. Polycythaemia vera I. Clinical and laboratory manifestations
35. Polycythaemia rubra vera in pregnancy
36. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis
37. Portal vein thrombosis following splenectomy for hematologic disease: Prospective study with Doppler color flow imaging
38. Complications and causes of death in polycythaemia vera
39. Deep venous thrombosis and postsplenectomy thrombocytosis
40. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
41. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: Role of the lipoxygenase pathway
42. Physiopathology and course of polycythaemia vera as related to therapy
43. Polycythaemia and portal vein thrombosis
44. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
45. Demonstration that the cell plasma ratio of blood contained in minute vessels is lower than that of venous blood
46. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia
47. Studies of the bone marrow in polycythaemia vera and the evolution of myelofibrosis and second hematologic malignancies
48. Polycythaemia vera: The packed cell volume and the curious logic of the red cell mass
49. Normal ranges for packed cell volume and hemoglobin concentration in adults: Relevance to 'apparent polycythaemia'
50. Measurement of blood volume and red cell mass: Re-examination of 51Cr and 125I methods
51. Treatment of polycythaemia: The reticulocyte response to venesection, phenylhydrazin and radiation
52. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders
53. Polycythaemia rubra vera and pregnancy
54. Iron metabolism haematopoiesis following phlebotomy iron as a limiting factor
55. Relief of intractable pruritus in polycythaemia vera with recombinant interferon alfa
56. Pruritis in polycythaemia vera: Treatment with aspirin and possibility of platelet involvement
57. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera
58. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count
59. Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy
60. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: Association with myeloid metaplasia and peripheral bone marrow extension
61. Homocysteine levels in polycythaemia vera and essential thrombocythaemia
62. Polycythaemia vera: The natural history of 1213 patients followed for 20 years
63. Low-dose aspirin in polycythaemia vera: A pilot study
64. Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial
65. Polycythaemia vera in the childbearing age
66. Antiphospholipid antibodies and essential thrombocythemia
67. Polycythaemia
68. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
69. The effect of interferon alpha on myeloproliferation and vascular complications in polycythaemia vera
70. The control of polycythaemia vera by venesection
71. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythaemia vera
72. The influence of anaemia, polycythaemia and splenomegaly on the relationship between venous haematocrit and red-cell volume
73. Actual and predicted normal red-cell and plasma volumes in primary and secondary polycythaemia
74. Polycythaemia vera and myelofibrosis
75. Skin mast cells in polycythaemia vera: Relationship to the pathogenesis and treatment of pruritus
76. Essential thrombocythemia in two sisters originating from different stem cell levels
77. Efficacy of phototherapy on severe pruritis in polycythaemia vera
78. Erythropoietin-independent colony growth in polycythaemia vera is not restricted to progenitor cells with trisomy of chromosome 8
79. Uncontrolled thrombocytosis in chronic myeloproliferative disorders
80. Danazole is safe and effective in relieving refractory pruritis in patients with myeloproliferative disorders and other diseases
81. Polycythaemia vera: Bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan
82. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes
83. Erythromelalgia and myeloproliferative disorders
84. Platelet survival in active polycythaemia vera with reference to the haematocrit level. An experimental study before and after phlebotomy
85. Prognostic factors in idiopathic (primary) osteomyelofibrosis
86. APC resistance as an additional thrombotic risk factor in a patient suffering from polycythaemia vera and recurrent thrombosis
87. Inapparent polycythaemia vera: An unrecognized diagnosis
88. Acute leukemia in polycythaemia vera
89. The nature and treatment of polycythaemia vera
90. Interferon α in the treatment of polycythaemia vera
91. Melphalan therapy of polycythaemia vera
92. Myeloproliferative syndrome
93. Portal system thrombosis after splenectomy for neoplasm or chronic hematologic disorder: Is routine surveillance imaging necessary?
94. Polycythaemia vera with myelofibrosis and myeloid metaplasia. Acute hepatic failure following splenectomy
95. Fibrosis of the bone marrow: Content and causes
96. Early postoperative course following elective splenectomy in haema-tological diseases: A high complication rate in patients with myeloproliferatuve disorders
97. Angiogenesis and angiogenic mediators in haematological malignancies
98. Polycythaemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone
99. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases
100. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
101. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: Retrospective study from one centre
102. Cytogenetic conversion in case of polycythaemia vera treated with interferon-alpha
103. Erythromelalgia and vascular complications in polycythaemia vera
104. The development of anaemia; the relation to leukemia; consideration of the basal metabolism, blood formation and destruction and fragility of the red cells
105. Polycythaemia vera and leukemia - The role of radiation treatment
106. Benign erythrocytosis
107. In vitro growth and differentiation kinetics of peripheral blood progenitor cells in polycythaemia vera
108. Oral psoralen photochemotherapy (PUVA) for pruritus associated with polycythaemia vera and myelofibrosis
109. Long-term treatment with interferon-alpha 2b for severe pruritis in patients with polycythaemia vera
110. Arterial studies in primary and secondary polycythemic disorders
111. The circulatory effects of haematocrit variations in normovolemic and hypervolemic dogs
112. Treatment of polycythaemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
113. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age
114. Erythrokinetic studies in myelofibrosis: Their significance for prognosis
115. Pure erythrocytosis: Reappraisal of a study of 51 cases
116. The 'spent' phase of polycythaemia vera: Hypersplenism in the absence of myelofibrosis
117. Polycythaemia vera in young people: An analysis of 58 cases diagnosed before 40 years
118. Acute leukemia and myelodysplasia in polycythaemia vera. A clinical study with long-term follow-up
119. The very-long-term course of polycythaemia: A complement to the previously published data of the Polycythaemia Vera Study group
120. Leukemic transformation in polycythaemia vera: Analysis of risk factors
121. Chronic cyanosis, with polycythaemia and enlarged spleen: A new clinical entity
122. Splenic irradiation in myelofibrosis clinical findings and ferrokinetics
123. Efficacy of pipobroman in the treatment of polycythaemia vera: Long-term results in 163 patients
124. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia
125. Viscosity and iron deficiency in treated polycythaemia
126. Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values
127. Familial myeloproliferative syndrome
128. Polycythaemia vera: Clinical studies on a series of 127 patients managed without radiation therapy
129. Splenic vein thrombosis after splenectomy: Frequency and role of imaging
130. Cytogenetic remission induced by interferon-alpha in a myeloproliferative disorder with trisomy 8
131. Polycythaemia vera treated with pipobroman as single agent: Low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-91)
132. Transitional myeloproliferative disorder
133. Splenectomy in agnogenic myeloid metaplasia
134. Letter: Bone-marrow responses in polycythaemia vera
135. Effect of therapy on blood volume, blood pressure, and spleen size in polycythaemia vera
136. The significance of thrombocytosis in old age
137. Low risk essential thrombocytosis
138. Non-hematologic effects of chronic iron deficiency. A study of patients with polycythaemia vera treated solely with venesections
139. Thrombotic complications in essential thrombocythemia with relatively low platelet counts
140. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases
141. Polycythaemia vera and myelosclerosis: A bone marrow study
142. Effect of splenomegaly on blood volume
143. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
144. No treatment for low-risk thrombocythaemia: Results from a prospective study
145. Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survival
146. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythaemia vera
147. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia
148. Alfa-interferon in the treatment of essential thrombocythemia: Clinical results and evaluation of its biological effects on the haematopoietic neoplastic clone
149. Pruritis and severe iron deficiency in polycythaemia vera
150. Spontaneous remission during two pregnancies in a patient with essential thrombocythaemia
151. Simultaneous measurement of plasma volume and cell mass in polycythaemia of high altitude
152. Platelet millionaires
153. Thromboembolic complications of polycythaemia: Polycythaemia vera versus smokers' polycythaemia
154. Blood volume in congenital cyanotic heart disease: Simultaneous measurements with Evans blue and radioactive phosphorus
155. Circulatory studies in polycythaemia vera at rest and during exercise
156. Expression of Bcl-x in erythroid precursors from patients with polycythaemia vera
157. A new treatment for polycythaemia vera: Recombinant interferon alfa
158. Interferon alfa: Effects of long-term treatment for polycythaemia vera
159. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
160. Nomnmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
161. Comparative values of Welcker, carbon monoxide and dye methods for blood volume determinations. Accurate estimation of absolute blood volume
162. Smokers' polycythaemia
163. Relationship of the plasma volume and the cell plasma ratio to the total red cell volume
164. The therapeutic use of venesection in polycythaemia
165. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
166. Evaluation of radiophosphorus therapy in primary polycythaemia
167. Significance of measurement of plasma volume and of indirect estimation of red cell volume
168. Phototherapy treatment of pruritis associated with polycythaemia vera
169. A prospective long-term cytogenetic study in polycythaemia vera in relation to treatment and clinical course
170. The haematological complications of polycythaemia vera and treatment with radioactive phosphorus
171. Polycythaemia vera and its treatment with radioactive phosphorus
172. Reversal of bone marrow fibrosis and subsequent development of polycythaemia inpatients with myeloproliferative disorders
173. Current status of antiangiogenic factors
174. Adverse effects of antiaggregating platelet therapy in the treatment of polycythaemia vera
175. Myeloproliferative disorders: Usefulness of X-linked probes in diagnosis
176. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia
177. 2-Chlorodeoxy-adenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia
178. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients
179. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia
180. The liver and spleen in polycythaemia vera
181. The prognosis of polycythaemia vera
182. Polycythaemia vera and gout: Report of eight cases
183. Massive hepatomegaly following splenectomy for myeloid metaplasia. Case report and review of the literature
184. A study of hematological complications occurring in patients with polycythaemia vera treated with 32-P (based on a series of 296 patients)
185. Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder
186. Mood and cognitive side effects of interferon-alpha therapy
187. Limitations of measuring blood volume with iodinated I, 125 serum albumin
188. The treatment of polycythaemia rubra vera with single doses of radioactive phosphorus
189. Polycythaemia vera. Course and prognosis
190. Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients
191. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome
192. The treatment of polycythaemia. A panel discussion
193. The management of polycythaemia vera
194. Polycythaemia vera - Its course and treatment relation to myeloid metaplasia and leukemia
195. The treatment of polycythaemia vera
196. Surgical bleeding in polycythaemia vera
197. Influence of therapy on causes of death in polycythaemia vera
198. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors
199. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients
200. The use of cimetidine for the treatment of pruritis in polycythaemia vera
201. The red cell mass-arterial oxygen relationship in normal man
202. Polycythaemia vera terminating in acute leukaemia: A clinical, cytogenetic and morphologic study in 8 patients treated with alkylating agents
203. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications
204. Hydroxyurea in the treatment of polycythaemia vera: A prospective study of 100 patients over a 20-year period
205. Histamine metabolism in polycythaemia vera
206. Myelofibrosis with myeloid metaplasia: Pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly
207. On the biosynthesis of uric acid from glycine-N in primary and secondary polycythemia
208. The splenomegaly of myeloproliferative disorders: Effects on blood volume and red blood count